Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 815 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ticagrelor in addition to acetylsalicylic acid for prevention of stroke in patients with acute ischaemic stroke or transient ischaemic attack Ticagrelor (Brilique; AZD6140) Stroke Cardiovascular System 2019 View  |  Download
Tideglusib for congenital myotonic dystrophy Tideglusib (AMO-02; Zentylor; Nypta; NP031112) Myotonic dystrophy Genetic Disorders , Musculoskeletal System , Neurology 2020 View  |  Download
Timolumab for Primary Sclerosing Cholangitis Timolumab (BTT1023) Primary sclerosing cholangitis (PSC) Hepatology 2018 View  |  Download
Timrepigene emparvovec for choroideremia Timrepigene emparvovec (BIIB111; AAV2-REP1; NSR-REP1) Choroideremia Ophthalmology 2020 View  |  Download
Tirzepatide for treating type 2 diabetes mellitus Tirzepatide (LY3298176) Type 2 diabetes Endocrine Nutritional and Metabolic Disorders 2021 View  |  Download
Tisagenlecleucel for relapsed or refractory follicular lymphoma Tisagenlecleucel-T (Kymriah; CTL019) Follicular lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Tisagenlecleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma – second line Tisagenlecleucel-T (Kymriah; CTL019) B-cell non-Hodgkin lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy Tislelizumab (BGB-A317; BGBA-317) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Tislelizumab for oesophageal cancer – second line Tislelizumab (BGB-A317; BGBA-317) Oesophageal cancer Head and Neck Cancer 2021 View  |  Download
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma Tislelizumab (BGB-A317; BGBA-317) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
1 2 71 72 73 74 75 81 82
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications